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Edited by Robert BaroukiAbstract Recent studies have shown that p21-activated kinase 1
(Pak1) phosphorylates estrogen receptor- (ER) at Ser 305 and
also promotes its transactivation function. Here, we sought to
investigate whether substitution of serine 305 in ER with
glutamic acid (ER-S305E), which mimics the phosphorylation
state, would inﬂuence the status of ER-target genes. To explore
this possibility, we generated clones overexpressing ER-S305E in
ER-negative MDA-MB-231 cells and analyzed the status of ER-
regulated genes using a gene array. Results indicated that the
expression of ER-S305E is suﬃcient to upregulate the expres-
sion of a few but not all ER-regulated genes, i.e., cyclin D1 and
zinc ﬁnger protein 147 (estrogen-responsive ﬁnger protein), while
there was no signiﬁcant change in the expression of remaining
genes on the array. In addition, we found an increased expression
as well as nuclear accumulation of cyclin D1 protein in MDA-
MB-231 cells expressing ER-S305E as compared to the level of
cyclin D1 in MDA-MB-231 cells expressing WT-ER or pcDNA.
Furthermore, ER-S305E, but not mutation of ER-S305 to
alanine, enhanced the cyclin D1 promoter activity. These
ﬁndings suggest that ER activation at S305 is suﬃcient to
upregulate the expression of cyclin D1, an ER-regulated gene
that is implicated in the progression of breast cancer. Phosphor-
ylation of ER by Pak1 or its upstream regulators could
upregulate the expression of a subset of ER-target genes in a
ligand-independent manner and hence, might contribute toward
the development of hormone independence in breast cancer cells.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The small GTPases, including Cdc42 and Rac1, have been
implicated in the regulation of mammalian cell morphology and
motility [1]. More speciﬁcally, Rac1 induces cortical actin po-
lymerization seen as membrane ruﬄing and lamellipodia, and
Cdc42 induces the formation of peripheral actin microspikes
and ﬁlopodia [2–4]. The small GTPases regulate the formation
of cytoskeletal structures via a family of serine/threonine kinases
known as p21-activated kinases (Paks). Activation of Pak1 is* Corresponding author. Fax: +l-713-745-3792.
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hesion complexes as well as maintenance of the integrity of the
motile leading edge [5,6]. Pak1 is activated by a number of ex-
tracellular signals, including heregulin (HRG) and epidermal
growth factor (EGF), which are potent inducers of Pak1 activity
and cell motility of breast cancer cells [7,8]. Activation of Pak1
involves autophosphorylation of several sites, including threo-
nine 423 (T423) within the auto-inhibitory loop of the kinase [9].
Accordingly, Pak1 phosphorylation at T423 has been linked
with its activation, as substitution of the acidic residue glutamic
acid (E) at this site yields a constitutively active T423E Pak1
enzyme [9,10]. In addition to its cytoskeleton eﬀects, Pak1 also
activates JNK and ERK kinases, and thus inﬂuences nuclear
signaling [11,12].
Recent studies suggest that in addition to cell motility, Pak1 is
also involved in breast cancer progression. Adam et al. [13] have
shownamechanistic role for Pak1activation in the increased cell
invasion of breast cancer cells by HRG. Furthermore, expres-
sion of a kinase-dead Pak1 mutant in the highly invasive breast
cancer cell lines MDA-MB-435 and MDA-MB-231 led to sta-
bilization of stress ﬁbers, enhanced cell spreading and reduction
in invasiveness [14]. Conversely, hyperactivation of the Pak1
pathway by conditional expression of catalytically active T423E
Pak1 in the non-invasive breast cancer cell lineMCF-7 promotes
cell migration and anchorage-independent growth [15]. Fur-
thermore, increased Pak1 activity correlates well with the inva-
siveness of human breast cancer cells and tumors [15]. Emerging
data suggest that Pak1 may be overexpressed in human cancers.
For example, Pak1 gene ampliﬁcation has been also reported in
ovarian [16] and breast [17] cancers. Furthermore, Pak1 protein
has been shown to be upregulated in ovarian tumors [16] and
breast cancer [15,18,19].
Overexpression of cyclin D1 has been noted in over 50% of
human breast tumors of all histological types [20–22]. Cyclin
D1 overexpression is found at the earliest stages of breast
cancer progression such as ductal carcinoma in situ and
maintained in all stages of metastasis [23]. The expression of
cyclin D1 is regulated by diverse signaling cascades [20–23]. In
addition, upregulation of cyclin D1 by estrogen receptor-a
(ERa) signaling is accompanied by an increased proliferative
response in breast cancer cells [24,25], as ERa-stimulated
proliferation could be eﬀectively blocked by antisense cyclin
D1 [25]. Upregulation of cyclin D1 expression has also been
found in hyperplastic mammary glands and proliferative hu-
man breast disease [26,27]. Together, these observations sug-
gest that cyclin D1 may constitute an important downstreamblished by Elsevier B.V. All rights reserved.
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gland development and tumorigenesis.
More recently, Pak1hasbeen shown todirectly phosphorylate
ERa at Ser305 and to promote its transactivation functions [28].
Additionally, expression of kinase-active T423E Pak1 transgene
in mammary glands induces hyperplasia in the mammary epi-
thelium [28], a phenotypemanifested by several other oncogenes
including cyclin D1 [20]. To directly implicate the ERa-S305 in
the biology of breast cancer cells, here we investigated whether
activation of ERa by replacing serine with glutamic acid at
residue 305 can upregulate estrogen signaling pathway genes
using an estrogen signaling pathway gene array.Fig. 1. Characterization of stable clones expressing ERa-S305E. Total
cell lysates from ERa-S305E, WT-ERa and pcDNA expressing clones
were analyzed by Western blotting with an anti-T7 monoclonal anti-
body. Vinculin was used as a loading control.2. Materials and methods
2.1. Cell cultures and reagents
MDA-MB-231 human breast cancer cells were maintained in Dul-
becco’s modiﬁed Eagle’s medium F12 (1:1) supplemented with 10%
fetal calf serum. Antibodies were purchased from the following com-
panies: anti-cyclin D1 from the Santa Cruz Biotechnology, Santa Cruz,
CA, and anti-Vinculin from Sigma. The anti-T7 epitope antibody was
purchased from Upstate Biotechnology, Inc. (Lake Placid, NY).
2.2. Generation of stable cell lines
MDA-MB-231 cells stably expressing pcDNA, T7-ERa-S305E and
T7-WT-ERa were generated by transfecting pcDNA, pcDNA-T7-
ERa-S305E and pcDNA-T7-WT-ERa by using the calcium phosphate
method. Forty eight hours after transfection, cells were selected by
G418 (1 mg/ml) selection. Approximately 50 clones were isolated.
Twenty clones were screened for the selection of individual clones.
2.3. Cell extracts and immunoblotting assays
For preparation of cell extracts, cells were washed 3 with phos-
phate-buﬀered saline and lysed in buﬀer (50 mM Tris–HCl, pH 7.5; 120
mM NaCl; 1% Triton X-100; 100 mM NaF; 200 mM NaVO5; 1 mM
PMSF and protease inhibitor cocktail (Gibco)) for 15 min on ice. The
lysates were centrifuged in an Eppendorf centrifuge at 4 C for 15 min.
Cell lysates containing equal amounts of protein were resolved on a
10% SDS–PAGE, transferred to nitrocellulose and probed with the
appropriate antibodies, using an ECL method. Vinculin expression
was used as protein loading control.
2.4. RNA isolation and cDNA array analysis
Total RNA was isolated using TRIzol reagent (Invitrogen) following
the manufacturer’s protocol. Aliquots of RNA (5–10 lg) were used to
analyze gene expression of estrogen signaling pathway (Cat #
hGEA9914010) by GE array technology as per the manufacturer’s
instructions (SuperArray, Inc., Bethesda, MD). Relative amounts of
mRNA transcripts were quantiﬁed using Molecular Imager System
and GE Array Analyzer version 1.3 software. The relative amount of a
given gene transcript was estimated by background substraction and
normalizing the signal with the signal derived from b-actin.
2.5. Immunoﬂuorescence and confocal imaging
Cells were plated on glass coverslips in six-well culture plates. After
24 h, the cells were rinsed in PBS, ﬁxed in 4% paraformaldehyde and
then processed for routine immunoﬂuorescent localization of cyclin
D1, T7-tag and F-actin (using Alexa-568-labeled Phalloidin, Molecular
Probes, Inc., Eugene, OR). The DNA was visualized by counter-
staining with ToPro3 (Molecular Probes). Fluorescent labeling was
visualized using a Zeiss LSM 510 microscope and a 63 objective.
2.6. Cyclin D1 promoter–reporter assays
Subconﬂuent MDA-MB-231 cells cultured in six-well plates were
transiently cotransfected with 0.5 lg of )1745 bp cyclin D1 promoter–
luciferase reporter construct [19], 1 lg of WT-ER, ERa-S305E and
ERa-S305A [28], and 10 ng of b-galactosidase using the FuGENE-6
reagent according to manufacturer’s protocol (Roche Molecular Bio-
chemicals, Indianapolis, IN). Twenty four hours after transfection,cells were lysed with passive-lysis buﬀer and luciferase assay was per-
formed using Luciferase Reporter Assay Kit (Promega, Madison, WI).
b-Galactosidase activity was used to normalize the transfection. Each
transfection was performed in triplicate wells [19].
2.7. Statistical analysis
Statistical analysis was done using Student’s t-test and values with
p < 0:05 were considered statistically signiﬁcant.3. Results and discussion
Earlier work from this laboratory has shown that Pak1
phosphorylates ERa at Ser305 and promotes transactivation
functions of ER [28] and that Pak1 regulates cyclin D1 ex-
pression in mammary epithelial and breast cancer cell lines
[19]. Since ER signaling has been shown to upregulate cyclin
D1 expression [24,25] and because an ER serine 305 to glu-
tamic acid mutant (ER-S305E) mimics Pak1 phosphorylation,
we tested the possibility whether Pak1 activation of ERa-
S305E is suﬃcient to inﬂuence the status of estrogen-inducible
genes. To address this hypothesis, we ﬁrst generated stable
clones from ER-negative MDA-MB-231 cells expressing T7-
tagged ERa-S305E or T7-WT-ERa or pcDNA. We charac-
terized four individual pcDNA-T7-ERa-S305E clones, three
individual pcDNA control vectors and T7-WT-ERa express-
ing clones. Immunoblot analysis of the cell lysates from ex-
ponentially growing cells revealed the expression of T7-ERa in
ERa-S305E and WT-ERa stable clones (Fig. 1).
The eﬀect of ERa-S305E substitution on ER-responsive
genes was studied using a human estrogen signaling pathway
gene array. Interestingly, of the 26 genes analyzed (Table 1),
expression of ERa-S305E signiﬁcantly enhanced only the ex-
pression of cyclin D1 and estrogen-responsive ﬁnger protein
[29], compared to the pcDNA clones, and there was no sig-
niﬁcant change on other genes spotted on the array (Fig. 2).
These results suggested that ERa-S305E expression is suﬃcient
to upregulate the expression of selected ER-regulated gene
such as cyclin D1 in a ligand-independent manner.
We next examined the expression of cyclin D1 protein in
ERa-S305E clones. Western blot analysis showed that over-
expression of ERa-S305E was accompanied by a 7–8-fold
upregulation of cyclin D1 protein expression compared to the
levels of cyclin D1 in the control clones (Fig. 3). To gain an
insight about the functional consequence of ER activation at
residue 305 and cyclin D1 expression, we determined the
subcellular distribution of cyclin D1 in ERa-S305E and WT-
ERa clones by quantitative confocal scanning microscopy.
Signiﬁcant induction of cyclin D1 expression was observed in
ERa-S305E clones compared to theWT-ERa and pcDNA con-
trol clones, and induced cyclin D1 predominantly accumulates
Table 1
Estrogen-regulated genes in the SuperArray
Position UniGene GeneBank Symbol Description Gene name
1 Hs.79241 M14745 BCL2 B-cell CLL/lymphoma 2 bcl-2
2 Hs.194143 U68041 BRCA1 Breast cancer 1, early onset BRCA1
3 Hs.79572 M11233 CTSD Cathepsin D (lysosomal aspartyl protease) Cathepsin D
4 N/A L08752 PUC18 PUC18 bacterial plasmid DNA PUC18
5 Hs.25647 V01512 FOS Human cellular oncogene c-fos c-fos
6 Hs.78465 J04111 JUN v-jun avian sarcoma virus 17 oncogene homolog c-jun
7 Hs.79070 X00364 MYC v-myc avian myelocytomatosis viral oncogene homolog c-myc
8 Hs.30888 AB007618 COX7A2L Cytochrome c oxidase subunit VIIa polypeptide 2 like COX7RP
9 Hs.82932 M64349 CCND1 Cyclin D1 (PRAD1: parathyroid adenomatosis 1) Cyclin D1
10 Hs.9222 AB007619 EBAG9 Estrogen receptor binding site associated, antigen, 9 EBAG9
11 Hs.288061 X00351 ACTB b-Actin b-Actin
12 Hs.1579 D21205 ZNF147 Zinc ﬁnger protein 147 (estrogen-responsive ﬁnger protein) EFP
13 Hs.2230 X04571 EGF Epidermal growth factor (b-urogastrone) EGF
14 Hs.77432 X00588 EGFR Epidermal growth factor receptor EGFR
15 Hs.1657 NM_000125 ESR1 Estrogen receptor a ER a
16 Hs.103504 AB006590 ESR2 Estrogen receptor b ER b
17 Hs.144321 NM_002128 HMG1 High mobility group protein 1 HMG1
18 Hs.169476 M33197 GAPDH Glyceraldehyde-3-phosphate dehydrogenase GAPDH
19 Hs.37003 NM_005343 HRAS v-Ha-ras Harvey rat sarcoma viral oncogene homolog H-ras
20 Hs.182265 NM_002276 KRT19 Keratin 19 Keratin 19
21 Hs.2905 M15716 PGR Progesterone receptor PR
22 Hs.1905 M29386 PRL Prolactin PRL
23 Hs.1406 NM_003225 TFF1 Trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in) pS2
24 Hs.115256 AF015950 TERT Telomerase reverse transcriptase Telomerase
25 Hs.170009 NM_003236 TGFA Transforming growth factor, a TGF-a





































































Fig. 2. Eﬀect of ERa-S305E on estrogen-responsive genes. Total RNA was isolated from pcDNA and ERa-S305E expressing clones. Aliquots of 5 lg
RNA were taken and hybridized to the cDNA array of estrogen-responsive signaling pathway as per the manufacturer’s instructions
([hGEA9912080], SuperArray, Bethesda, MD). Quantitation of the cDNA array analysis in pcDNA and ERa-S305E clones using a Molecular
Imager System and GE Array Analyzer version 1.3 software.
Fig. 3. ERa-S305E upregulates cyclin D1 expression. Total cell lysates
from ERa-S305E, WT-ERa and pcDNA expressing clones were ana-
lyzed for cyclin D1 by Western blotting with an anti-cyclin D1
monoclonal antibody. Vinculin was used as a loading control.
S. Balasenthil et al. / FEBS Letters 567 (2004) 243–247 245in the nucleus (Fig. 4, upper panel). Transgene expression in
ERa-S305E and WT-ERa clones was validated using confocal
microscopy (Fig. 4, bottom panel).
Because ERa-S305E stimulated the expression of cyclin D1
(this study), we further studied the eﬀect of ERa-S305E on
cyclin D1-luciferase reporter driven promoter activity. As ex-
pected, the ERa-S305E mutant, but not ERa-S305 to alanine
mutant (S305A) [28], resulted in a signiﬁcant induction of cyclin
D1 promoter activity as compared to the WT-ERa (Fig. 5A).
Together, these ﬁndings suggest that ERa phosphorylation
Fig. 4. Eﬀect of ERa-S305E on cyclin D1 expression and localization. MDA-MB-231 cells stably expressing pcDNA, WT-ERa and ERa-S305E were
ﬁxed in 4% paraformaldehyde and immunoﬂuorescently stained for endogenous cyclin D1 (green), T7-tag (green), actin (red) and counterstained for





































Fig. 5. Eﬀect of ERa-S305E and ERa-S305A on cyclin D1 promoter
activity. (A) MDA-MB-231 cells were cotransfected with 0.5 lg of
cyclin D1-luciferase reporter, 1.0 lg of WT-ERa, ERa-S305E or ERa-
S305A and 10 ng of b-galactosidase. After 24 h, the cells were lysed
and luciferase activity was measured. The activity was normalized with
b-galactosidase activity. P < 0:05. (B) Schematic representation of the
proposed working model.
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the ER pathway via Pak1.
In addition to its natural ligand estrogen, ER has also
been shown to be activated by a variety of growth factors
[30,31] and because growth factors have been implicated in
the development of hormone independence [30,31], our
ﬁndings presented here suggest a model wherein upstreamsignals such as growth factors leading to Pak1 activation
may potentially activate ER at Ser305 and thus regulate the
expression and nuclear functions of cyclin D1. We have re-
cently shown that these functions also can be regulated via
NF-jB by Pak1 [19] (Fig. 5B). Since Pak1 regulation of ER
at S305 is independent of estrogen [28], it is very likely that
this noted ligand-independent increase in cyclin D1 expres-
sion might contribute towards the development of hormone-
independent phenotypes.Acknowledgements: We thank Mahitosh Mandal for the initial char-
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